or Try an Advanced Search...

    Technical Analysis for CYBN - Cybin Inc.

    Grade Last Price % Change Price Change
    F 0.36 -1.99% -0.01
    CYBN closed down 1.99 percent on Monday, April 22, 2024, on 39 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CYBN trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.00%
    Doji - Bearish? Reversal 0.00%
    Outside Day Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -1.99%
    Narrow Range Bar Range Contraction -1.99%
    Down 3 Days in a Row Weakness -1.99%
    Gapped Down Weakness -1.99%
    Older End-of-Day Signals for CYBN ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 18 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    Outside Day about 22 hours ago
    Fell Below Previous Day's Low about 22 hours ago
    Down 2 % about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    CYBN Chart by TradingView
    Basic chart:

    Profile

    Cybin Inc. Description

    Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Drugs Major Depressive Disorder Neurochemistry Psychedelic Drug

    Is CYBN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
    Apr 16 Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
    Mar 30 Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
    Mar 19 Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
    Mar 18 Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
    Mar 15 Cybin initiates Phase 2 study for psychedelic drug DMT
    Mar 15 Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
    Mar 14 Cybin to begin Phase 3 study for psychedelic drug mid-year
    Mar 14 Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
    Mar 13 Cybin launches $150M oversubscribed private placement
    See more CYBN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.738
    52 Week Low 0.21
    Average Volume 5,794,722
    200-Day Moving Average 0.42
    50-Day Moving Average 0.39
    20-Day Moving Average 0.40
    10-Day Moving Average 0.38
    Average True Range 0.03
    RSI (14) 40.12
    ADX 19.6
    +DI 16.86
    -DI 19.45
    Chandelier Exit (Long, 3 ATRs) 0.39
    Chandelier Exit (Short, 3 ATRs) 0.43
    Upper Bollinger Bands 0.46
    Lower Bollinger Band 0.35
    Percent B (%b) 0.13
    BandWidth 28.88
    MACD Line -0.01
    MACD Signal Line 0.00
    MACD Histogram -0.0071
    Fundamentals Value
    Market Cap 146.29 Million
    Num Shares 406 Million
    EPS -0.19
    Price-to-Earnings (P/E) Ratio -1.90
    Price-to-Sales 278.25
    Price-to-Book 3.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.40
    Resistance 3 (R3) 0.40 0.39 0.39
    Resistance 2 (R2) 0.39 0.38 0.39 0.39
    Resistance 1 (R1) 0.38 0.37 0.37 0.37 0.39
    Pivot Point 0.37 0.37 0.36 0.36 0.37
    Support 1 (S1) 0.35 0.36 0.35 0.35 0.33
    Support 2 (S2) 0.34 0.35 0.34 0.33
    Support 3 (S3) 0.33 0.34 0.33
    Support 4 (S4) 0.32